Tolar, Martin http://orcid.org/0000-0002-3910-091X
Abushakra, Susan
Hey, John A.
Porsteinsson, Anton
Sabbagh, Marwan
Funding for this research was provided by:
Alzheon, Inc.
National Institutes of Health (NIH COBRE 5P20GM109025, NIH R01 AG059008)
Keep Memory Alive Foundation
Article History
Received: 26 February 2020
Accepted: 30 July 2020
First Online: 12 August 2020
Ethics approval and consent to participate
: Not applicable
: Not applicable
: Dr. Martin Tolar serves as the Founder, President, and Chief Executive Officer of Alzheon, Inc. and holds stock and stock options of Alzheon, Inc.Dr. Susan Abushakra serves as the Chief Medical Officer of Alzheon, Inc. and holds stock and stock options of Alzheon, Inc.Dr. John A. Hey serves as the Chief Scientific Officer of Alzheon, Inc. and holds stock and stock options of Alzheon, Inc.Dr. Anton Porsteinsson receives research support from the National Institutes of Health and U.S. Department of Defense. He also receives grants from AstraZeneca, Avanir, Biogen, Biohaven, Eisai, Eli Lilly, Genentech/Roche, Janssen, Novartis, Merck, and Toyama. He receives personal fees from Acadia Pharmaceuticals, Avanir, BioXcel, Eisai, Functional Neuromodulation, Grifols, Lundbeck, Merck, Neurim Pharmaceuticals, Pfizer, Tetra Discovery Partners, and Toyama.Dr. Marwan Sabbagh receives research support from the NIH and the Keep Memory Alive Foundation. He has consulting agreements with Allergan, Biogen, Bracket, Cortexyme, Grifols, Sanofi, Neurotrope, and Roche-Genentech. He has ownership interest in Brain Health Inc., Versanum Inc., Neurotrope Inc., and uMethod Health.